- Home
- Therapeutics
- Cardiovascular
Cardiovascular/Metabolic clinical trials
ICON's cardiovascular trial experience, supported by a global team of experts
ICON has extensive experience in cardiovascular clinical research trials across the entire drug development spectrum.
Despite the advances in the cardio-metabolic field over the past 20 years, cardiovascular and metabolic diseases remain the leading causes of morbidity and mortality worldwide. The need to discover and develop better, safer and more cost-effective drugs and devices remains.
ICON, a full-service provider, takes a data-driven approach to develop strategies that will cut timelines and costs from First-in-Human (FIH) studies through post-approval. We have over 25 years of experience conducting cardiovascular trials with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.
ICON Cardiovascular experience in the last five years
-
36,415
Patients -
118
Studies -
3,929
Sites
ICON's experienced cardio-metabolic drug and medical device development teams support clinical trials across multiple indications, including:
-
Cardiovascular
- Atrial and Ventricular Arrhythmia
- Cardiomyopathy (e.g., ATTR, hypertrophic, etc. with rare disease team)
- Heart failure
- Hypertension
- Pulmonary Hypertension (with the respiratory team)
- Coronary Artery Disease and Stable Angina
- Acute Coronary syndromes, including myocardial infarction
- Venous Thromboembolism
- Peripheral Arterial Disease
-
Atherosclerotic & embolic cerebrovascular disease
- Stroke, TIA (with neurosciences team)
-
Metabolic
- Diabetes
- Dyslipidemia
- Hyperuricemia
- Medical Device & Diagnostics Research ICON has deep experience with the development and commercialisation of medical devices, medical device software, in vitro diagnostics, drug delivery systems/devices and combination products across all key cardiovascular indications.
- Adaptive Study Design Market-leading simulation software and methods to perfect trial design
- Early Phase Research Comprehensive early phase research network with pharmacy, labs, and cardiac safety monitoring.
- Feasibility Assessment Access to a global team of experts and data scientists using an evidence-based approach to accurately estimate enrolment and study timelines.
- Site & Patient Solutions Transforming recruitment through patient-centric trials and real-world, real-time data
- Medical Imaging Integrated solutions based on the science of imaging biomarkers and experience in all cardiovascular imaging modalities.
- Endpoint Adjudication Services Endpoint Adjudication can help lower the risk of variation in important clinical trial outcome events for submission to regulatory agencies.
- Central Laboratories Global central laboratories with industry-leading accuracy for CVM study endpoints.
Medical Device & Diagnostics Research
ICON has deep experience with the development and commercialisation of medical devices, medical device software, in vitro diagnostics, drug delivery systems/devices and combination products across all key cardiovascular indications.
Adaptive Study Design
Market-leading simulation software and methods to perfect trial design
Early Phase Research
Comprehensive early phase research network with pharmacy, labs, and cardiac safety monitoring.
Feasibility Assessment
Access to a global team of experts and data scientists using an evidence-based approach to accurately estimate enrolment and study timelines.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data
Medical Imaging
Integrated solutions based on the science of imaging biomarkers and experience in all cardiovascular imaging modalities.
Endpoint Adjudication Services
Endpoint Adjudication can help lower the risk of variation in important clinical trial outcome events for submission to regulatory agencies.
Central Laboratories
Global central laboratories with industry-leading accuracy for CVM study endpoints.
Dedicated specialist teams
ICON has a global team of in-house cardio-metabolic experts who are highly-experienced in clinical research and drug and device development. The group includes representatives from all critical functional areas and oversees trial operations in order to anticipate and proactively address potential roadblocks. We also leverage established and new relationships with renowned cardio-metabolic experts and investigators worldwide to benefit our clients.
In addition to providing support and guidance to the study team, our cardio-metabolic experts provide insight on:
- Global project feasibility
- Protocol development, review and evaluation
- Clinical trial planning
- Therapeutic training and advice
- Project oversight
- Consulting, medical monitoring and advisory board representation
- Interpretation of the clinical data
- Completion of the clinical study report
Accellacare
Our global investigator database includes over 5,800 cardiovascular investigative sites across more than 55 countries. As such, we have established solid working relationships with leading cardiovascular sites in all regions of the world, enabling us to provide our sponsors with efficient recruitment strategies tailored to each study.
Cardiovascular, Metabolic and Circulation insights
ICON's Cardiovascular team contributes regularly to industry publications and media coverage of cardiovascular clinical trials. Stay up to date with ICON's latest thought leadership on cardiovascular clinical trials.
In this section
-
Biosimilars
-
Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
- Endocrine & Metabolic Disorders
- Infectious Diseases
- Internal Medicine & Immunology
-
Medical Device
- Oncology
-
Paediatrics
- Rare & Orphan Diseases
- Vaccines
-
Women's Health
-
Therapeutics insights
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Women's Health Insights
-
Oncology
- Paediatrics
-
Rare and orphan diseases
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research